Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 423

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Metabolic Syndrome in Type 1 Diabetes

Open access
Thorn, Lena M., Forsblom, Carol, Fagerudd, Johan, Thomas, Merlin C., Pettersson-Fernholm, Kim, Saraheimo, Markku, Wadén, Johan, Rönnback, Mats, Rosengård-Bärlund, Milla, Björkesten, Clas-Göran af, Taskinen, Marja-Riitta, Groop, Per-Henrik, on behalf of the FinnDiane Study Group·2005·Diabetes Care

Abstract

OBJECTIVE—The aim of this study was to estimate the prevalence of the metabolic syndrome in Finnish type 1 diabetic patients and to assess whether it is associated with diabetic nephropathy or poor glycemic control. RESEARCH DESIGN AND METHODS—In all, 2,415 type 1 diabetic patients (51% men, mean age 37 years, duration of diabetes 22 years) participating in the nationwide, multicenter Finnish Diabetic Nephropathy (FinnDiane) study were included. Metabolic syndrome was defined according to the National Cholesterol Education Program diagnostic criteria. Patients were classified as having normal albumin excretion rate (AER) (n = 1,261), microalbuminuria (n = 326), macroalbuminuria (n = 383), or end-stage renal disease (ESRD) (n = 164). Glycemic control was classified as good (HbA1c <7.5%), intermediate (7.5–9.0%), or poor (>9.0%). Creatinine clearance was estimated with the Cockcroft-Gault formula. RESULTS—The overall prevalence of metabolic syndrome was 38% in men and 40% in women. The prevalence was 28% in those with normal AER, 44% in microalbuminuric patients, 62% in macroalbuminuric patients, and 68% in patients with ESRD (P < 0.001). Patients with metabolic syndrome had a 3.75-fold odds ratio for diabetic nephropathy (95% CI 2.89–4.85), and all of the separate components of the syndrome were independently associated with diabetic nephropathy. The prevalence of metabolic syndrome was 31% in patients with good glycemic control, 36% in patients with intermediate glycemic control, and 51% in patients with poor glycemic control (P < 0.001). Similarly, metabolic syndrome increased with worsening creatinine clearance. CONCLUSIONS—The metabolic syndrome is a frequent finding in type 1 diabetes and increases with advanced diabetic nephropathy and worse glycemic control.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diacare.28.8.2019

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 423

Metadata

Authors
Thorn, L. M., Forsblom, C., Fagerudd, J., Thomas, M. C., Pettersson-Fernholm, K., Saraheimo, M., Wadén, J., Rönnback, M., Rosengård-Bärlund, M., Björkesten, C.-G. A., Taskinen, M.-R., Groop, P.-H., & on behalf of the FinnDiane Study Group
Venue
Diabetes Care
Published
2005-08-01
Volume
28
Issue
8
Pages
2019-2024
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2045666817
Cited by
423
References
35
FWCI
11.44
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolic Syndrome in Type 1 Diabetes. https://app.cochat.ai/papers/10.2337/diacare.28.8.2019
The paper
Thorn, L. M., Forsblom, C., Fagerudd, J., Thomas, M. C., Pettersson-Fernholm, K., Saraheimo, M., Wadén, J., Rönnback, M., Rosengård-Bärlund, M., Björkesten, C.-G. A., Taskinen, M.-R., Groop, P.-H., & on behalf of the FinnDiane Study Group. (2005). Metabolic Syndrome in Type 1 Diabetes. Diabetes Care. https://doi.org/10.2337/diacare.28.8.2019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.